Journal:

Article Title: prbA , a Gene Coding for an Esterase Hydrolyzing Parabens in Enterobacter cloacae and Enterobacter gergoviae Strains

doi: 10.1128/JB.184.18.5011-5017.2002

Figure Lengend Snippet: Origin of strains, MICs, and hydrolytic ability

Article Snippet: The presence of homologues of prbA in selected strains was determined by touchdown PCR with the primers and conditions specified above. table ft1 table-wrap mode="anchored" t5 TABLE 1. caption a7 Strain designation Origin MIC (mg liter −1 ) f Degradation (%) g E. cloacae EM a Mineral supplement >3,200 99.9 ID 67037 b Clinical strain 3,200 12.7 ID 67284 b Clinical strain 3,200 12.8 LSPQ 3022 Reference strain 3,200 15.3 LSPQ 3345 Reference strain 3,200 19.2 E. gergoviae G1 c Eye liner >3,200 100 G2 c Foundation 3,200 10.3 G3 c Exfoliating gel 3,200 8.9 G4 c Foundation 3,200 8.5 G5 c Clinical strain 3,200 7.8 G6 c Cream 3,200 10.4 G7 c Challenge test 3,200 14.7 G8 c Shampoo 3,200 14.4 G9 c Cream 3,200 11.4 G10 c Shampoo 3,200 12.3 G11 c Cream 3,200 16.3 G12 c Rinsing material 3,200 97.9 G13 c Clinical strain 1,600 15.5 G14 c Clinical strain 3,200 20.0 G15 c Clinical strain 3,200 22.6 GM a Mineral supplement 3,200 18.7 WL d Syrup 3,200 14.8 LSPQ 3347 Reference strain 3,200 14.0 ATCC 33028 Reference strain 3,200 12.6 ATCC 33426 Reference strain 3,200 14.7 ATCC 33428 Reference strain 3,200 18.1 E. aerogenes AE1 c Clinical strain 3,200 15.4 AE1 c Clinical strain 3,200 12.7 AE1 c Clinical strain 3,200 14.7 LSPQ 3811 Reference strain 3,200 15.6 ATCC 13048 Reference strain 3,200 12.9 P. agglomerans ID 60635 b Clinical strain 3,200 10.1 ID 65518 b Clinical strain 3,200 14.4 LSPQ 3353 Reference strain 1,600 14.5 LSPQ 3825 Reference strain 800 13.5 E. coli ID 41839 e Clinical strain 3,200 9.1 ATCC 25922 Reference strain 1,600 12.6 ATCC 35218 Reference strain 3,200 11.3 B. cepacia IFO 15124 Oil-in-water emulsion 1,600 37.9 P. aeruginosa ID 33122 e Clinical strain 3,200 12.4 ATCC 33350 Reference strain 1,600 10.2 Open in a separate window a Provided by a private company in Quebec, Canada. b Provided by the “Laboratoire de Santé Publique” (LSPQ), Quebec, Canada. c Provided by C. Bollet, Faculty of Medicine, INSERM, Marseille, France. d Provided by a private company in Ontario, Canada. e Provided by the Maisonneuve-Rosemont Hospital, Montreal, Canada. f Expressed as the concentration of methyl paraben. g Expressed as the percentage of 800 ppm (5.7 mM) of methyl paraben degraded after 2 h of incubation by an exponentially growing culture.

Techniques: